Ollila TA - Search Results

1

Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record.

Zayac AS, Hilliard RW, Olszewski AJ, Pelcovits A, Reagan JL, Hsu A, Riley D, Austin M, Ollila TA. Zayac AS, et al. Among authors: ollila ta. R I Med J (2013). 2020 Oct 1;103(8):78-83. R I Med J (2013). 2020. PMID: 33003686 Free article.

2

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.

Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Ollila TA, et al. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29433979

3

Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.

Olszewski AJ, Ollila T, Reagan JL. Olszewski AJ, et al. Br J Haematol. 2018 May;181(4):495-504. doi: 10.1111/bjh.15224. Epub 2018 Apr 24. Br J Haematol. 2018. PMID: 29687879 Free PMC article. Clinical Trial.

4

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.

Ollila TA, Olszewski AJ. Ollila TA, et al. Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. Curr Treat Options Oncol. 2018. PMID: 29931605 Free PMC article. Review.

5

Radiation therapy in primary testicular lymphoma: does practice match the standard of care?

Ollila TA, Olszewski AJ. Ollila TA, et al. Leuk Lymphoma. 2019 Feb;60(2):523-526. doi: 10.1080/10428194.2018.1480776. Epub 2018 Jul 3. Leuk Lymphoma. 2019. PMID: 29966467 Free PMC article. No abstract available.

6

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.

Ollila TA, Sahin I, Olszewski AJ. Ollila TA, et al. Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019. Onco Targets Ther. 2019. PMID: 30799938 Free PMC article. Review.

7

Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Ollila TA, Reagan JL, Olszewski AJ. Ollila TA, et al. Leuk Lymphoma. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. Epub 2019 Jul 9. Leuk Lymphoma. 2019. PMID: 31287335 Free PMC article.

8

Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study.

Di M, Ollila TA, Olszewski AJ. Di M, et al. Among authors: ollila ta. Leukemia. 2020 Oct;34(10):2794-2797. doi: 10.1038/s41375-020-0798-9. Epub 2020 Mar 17. Leukemia. 2020. PMID: 32203140 No abstract available.

9

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.

Ollila TA, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel NR, Dubielecka PM, Treaba DO, Olszewski AJ. Ollila TA, et al. Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236. Blood. 2021. PMID: 32877514 Free PMC article. No abstract available.

10

Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.

Ollila TA, Olszewski AJ. Ollila TA, et al. Cancer Manag Res. 2021 May 14;13:3935-3952. doi: 10.2147/CMAR.S267258. eCollection 2021. Cancer Manag Res. 2021. PMID: 34017197 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters